Big pharma can only see the benefit of R&D for wealthy markets | Kenan Malik

There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries

At the end of April, health workers in Malawi, Ghana and Kenya began rolling out the first and so far only vaccine proved to protect against malaria. It's part of a World Health Organization pilot programme that could immunise more than one million children by 2023. Yet, while this is a welcome step in the fight against malaria, it also exposes the problems in developing vaccines for use in non-western countries.

This kind of endeavour can't be repeated, from GSK's point of view